vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and VIRTUS INVESTMENT PARTNERS, INC. (VRTS). Click either name above to swap in a different company.
VIRTUS INVESTMENT PARTNERS, INC. is the larger business by last-quarter revenue ($208.0M vs $177.4M, roughly 1.2× Pacira BioSciences, Inc.). VIRTUS INVESTMENT PARTNERS, INC. runs the higher net margin — 16.3% vs 1.6%, a 14.6% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -10.9%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -3.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
VIRTUS INVESTMENT PARTNERS, INC.VRTSEarnings & Financial Report
Virtus Investment Partners, Inc. is an American company which operates as a multi-manager asset management business, comprising a number of individual affiliated managers, each having its own investment process and brand, and the services of unaffiliated sub advisers.
PCRX vs VRTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $208.0M |
| Net Profit | $2.9M | $33.9M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | 19.1% |
| Net Margin | 1.6% | 16.3% |
| Revenue YoY | 5.0% | -10.9% |
| Net Profit YoY | — | -14.2% |
| EPS (diluted) | $0.07 | $5.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $208.0M | ||
| Q3 25 | $179.5M | $216.4M | ||
| Q2 25 | $181.1M | $210.5M | ||
| Q1 25 | $168.9M | $217.9M | ||
| Q4 24 | $187.3M | $233.5M | ||
| Q3 24 | $168.6M | $227.0M | ||
| Q2 24 | $178.0M | $224.4M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $33.9M | ||
| Q3 25 | $5.4M | $31.3M | ||
| Q2 25 | $-4.8M | $42.7M | ||
| Q1 25 | $4.8M | $28.1M | ||
| Q4 24 | — | $39.5M | ||
| Q3 24 | $-143.5M | $49.1M | ||
| Q2 24 | $18.9M | $26.0M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 19.1% | ||
| Q3 25 | 3.5% | 21.7% | ||
| Q2 25 | 4.7% | 21.5% | ||
| Q1 25 | 1.2% | 16.8% | ||
| Q4 24 | 13.2% | 21.7% | ||
| Q3 24 | -82.8% | 24.3% | ||
| Q2 24 | 15.9% | 19.7% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 16.3% | ||
| Q3 25 | 3.0% | 14.5% | ||
| Q2 25 | -2.7% | 20.3% | ||
| Q1 25 | 2.8% | 12.9% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | -85.1% | 21.6% | ||
| Q2 24 | 10.6% | 11.6% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $5.15 | ||
| Q3 25 | $0.12 | $4.65 | ||
| Q2 25 | $-0.11 | $6.12 | ||
| Q1 25 | $0.10 | $4.05 | ||
| Q4 24 | $0.38 | $4.65 | ||
| Q3 24 | $-3.11 | $5.71 | ||
| Q2 24 | $0.39 | $2.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | — |
| Total DebtLower is stronger | — | $390.0M |
| Stockholders' EquityBook value | $653.9M | $934.0M |
| Total Assets | $1.2B | $4.3B |
| Debt / EquityLower = less leverage | — | 0.42× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | — | ||
| Q3 25 | $246.3M | — | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | — | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | — | ||
| Q2 24 | $404.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $390.0M | ||
| Q3 25 | $376.7M | $390.6M | ||
| Q2 25 | $580.5M | $231.3M | ||
| Q1 25 | $583.4M | $231.7M | ||
| Q4 24 | $585.3M | $232.1M | ||
| Q3 24 | — | $237.5M | ||
| Q2 24 | — | $247.6M |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $934.0M | ||
| Q3 25 | $727.2M | $918.7M | ||
| Q2 25 | $757.8M | $896.4M | ||
| Q1 25 | $798.5M | $893.7M | ||
| Q4 24 | $778.3M | $897.5M | ||
| Q3 24 | $749.6M | $889.0M | ||
| Q2 24 | $879.3M | $868.7M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $4.3B | ||
| Q3 25 | $1.3B | $3.9B | ||
| Q2 25 | $1.5B | $3.7B | ||
| Q1 25 | $1.6B | $3.7B | ||
| Q4 24 | $1.6B | $4.0B | ||
| Q3 24 | $1.5B | $3.6B | ||
| Q2 24 | $1.6B | $3.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.42× | ||
| Q3 25 | 0.52× | 0.43× | ||
| Q2 25 | 0.77× | 0.26× | ||
| Q1 25 | 0.73× | 0.26× | ||
| Q4 24 | 0.75× | 0.26× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-67.2M |
| Free Cash FlowOCF − Capex | — | $-74.1M |
| FCF MarginFCF / Revenue | — | -35.6% |
| Capex IntensityCapex / Revenue | — | 3.3% |
| Cash ConversionOCF / Net Profit | — | -1.99× |
| TTM Free Cash FlowTrailing 4 quarters | — | $100.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $-67.2M | ||
| Q3 25 | $60.8M | $108.3M | ||
| Q2 25 | $12.0M | $75.8M | ||
| Q1 25 | $35.5M | $-3.8M | ||
| Q4 24 | $33.1M | $1.8M | ||
| Q3 24 | $53.9M | $69.1M | ||
| Q2 24 | $53.2M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-74.1M | ||
| Q3 25 | $57.0M | $106.9M | ||
| Q2 25 | $9.3M | $74.2M | ||
| Q1 25 | $26.9M | $-6.8M | ||
| Q4 24 | $31.0M | $-3.8M | ||
| Q3 24 | $49.8M | $68.7M | ||
| Q2 24 | $51.6M | $68.6M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -35.6% | ||
| Q3 25 | 31.7% | 49.4% | ||
| Q2 25 | 5.1% | 35.2% | ||
| Q1 25 | 15.9% | -3.1% | ||
| Q4 24 | 16.6% | -1.6% | ||
| Q3 24 | 29.6% | 30.3% | ||
| Q2 24 | 29.0% | 30.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 3.3% | ||
| Q3 25 | 2.2% | 0.7% | ||
| Q2 25 | 1.5% | 0.7% | ||
| Q1 25 | 5.1% | 1.4% | ||
| Q4 24 | 1.1% | 2.4% | ||
| Q3 24 | 2.4% | 0.2% | ||
| Q2 24 | 0.9% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | -1.99× | ||
| Q3 25 | 11.20× | 3.45× | ||
| Q2 25 | — | 1.77× | ||
| Q1 25 | 7.37× | -0.13× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | 2.82× | 2.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
VRTS
| Open End Funds | $68.9M | 33% |
| Retail Separate Accounts | $51.3M | 25% |
| Institutional Accounts | $39.6M | 19% |
| Administration And Shareholder Service Fees | $18.4M | 9% |
| Closed End Funds | $15.9M | 8% |
| Distribution And Service Fees | $12.3M | 6% |
